Reported 737,138 shares, up 206,307 (38.9%) from the prior quarter.
Reported value 12.9%; share count 38.9% vs. the prior quarter.
Reported position value by quarter
Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.
| Date | Holding Value |
|---|---|
| 2021-12-31 | 96000 |
| 2022-03-31 | 159000 |
| 2022-06-30 | 118000 |
| 2022-09-30 | 57000 |
| 2022-12-31 | 47924 |
| 2023-03-31 | 35746 |
| 2023-06-30 | 67430 |
| 2023-09-30 | 51182 |
| 2023-12-31 | 55853 |
| 2024-03-31 | 0 |
| 2025-12-31 | 49076 |
| 2026-03-31 | 284305 |
| 2026-06-30 | 2070241 |
| 2026-09-30 | 2336727 |
Quarterly position history
How this manager's reported quarter-end position changed over time.
| Quarter | Activity | Shares | Change | % of reported 13F | Reported value | Filed | Source filing |
|---|---|---|---|---|---|---|---|
| Q3 2026 | Added | 737,138 | +206,307 (38.9%) | < 0.01% | $2,336,727 | 2026-11-12 | |
| Q2 2026 | Added | 530,831 | +456,600 (615.1%) | < 0.01% | $2,070,241 | 2026-08-07 | |
| Q1 2026 | Added | 74,231 | +61,109 (465.7%) | < 0.01% | $284,305 | 2026-05-15 | |
| Q4 2025 | New | 13,122 | +13,122 (0.0%) | < 0.01% | $49,076 | 2026-02-13 | |
| Q1 2024 | Reduced | 0 | -81,241 (-100.0%) | 0 | $0 | 2024-05-15 | |
| Q4 2023 | Unchanged | 81,241 | 0 (0.0%) | < 0.01% | $55,853 | 2024-02-14 | |
| Q3 2023 | Unchanged | 81,241 | 0 (0.0%) | < 0.01% | $51,182 | 2023-11-14 | |
| Q2 2023 | Unchanged | 81,241 | 0 (0.0%) | < 0.01% | $67,430 | 2023-08-14 | |
| Q1 2023 | Unchanged | 81,241 | 0 (0.0%) | < 0.01% | $35,746 | 2023-05-15 | |
| Q4 2022 | Unchanged | 81,241 | 0 (0.0%) | < 0.01% | $47,924 | 2023-02-14 | |
| Q3 2022 | Unchanged | 81,241 | 0 (0.0%) | < 0.01% | $57,000 | 2022-11-15 | |
| Q2 2022 | Added | 81,241 | +38,900 (91.9%) | < 0.01% | $118,000 | 2022-08-15 | |
| Q1 2022 | Added | 42,341 | +30,041 (244.2%) | < 0.01% | $159,000 | 2022-05-16 | |
| Q4 2021 | New | 12,300 | +12,300 (0.0%) | < 0.01% | $96,000 | 2022-02-14 |
Who else reported the position
106 managers reported SAB BIOTHERAPEUTICS INC for Q3 2026.
| Manager | Activity | Shares | Change | % of reported 13F | Reported value | Tenure |
|---|---|---|---|---|---|---|
| Caligan Partners LP | Added | 8,736,898 | +769,691 | 1.69% | $27,695,967 | 3 qtrs |
| Vivo Capital LLC | Reduced | 6,915,011 | -384,898 | 2.41% | $21,920,585 | 5 qtrs |
| PERCEPTIVE ADVISORS LLC | Unchanged | 6,627,501 | 0 | 0.37% | $21,009,178 | 4 qtrs |
| ADAGE CAPITAL PARTNERS GP L L C | Unchanged | 6,405,553 | 0 | 0.03% | $20,305,603 | 3 qtrs |
| RA CAPITAL MANAGEMENT L P | Unchanged | 4,401,500 | 0 | 0.14% | $13,952,755 | 5 qtrs |
| Balyasny Asset Management LLC | Unchanged | 3,760,439 | 0 | 0.01% | $11,920,592 | 4 qtrs |
| BlackRock Inc | Added | 3,572,073 | +506,057 | < 0.01% | $11,323,472 | 9 qtrs |
| MILLENNIUM MANAGEMENT LLC | Added | 3,453,920 | +704,833 | < 0.01% | $10,948,926 | 4 qtrs |
| VANGUARD CAPITAL MANAGEMENT LLC | Added | 3,088,536 | +115,607 | < 0.01% | $9,790,659 | 3 qtrs |
| COMMODORE CAPITAL LP | Unchanged | 2,870,000 | 0 | 0.7% | $9,097,900 | 5 qtrs |
Filing details and methodology As reported
- Report period
- September 30, 2026
- Filed
- November 12, 2026
- Filing type
- 13F-HR
- Position type
- COM NEW
Voting authority reported
- Sole
- 229,803
- Shared
- 0
- None
- 507,335
“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.
Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.